Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, telaprevir; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Atlanta, Georgia • Burlington, Vermont

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Hepatitis C
Interventions: Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b; Other · Biological
Lead sponsor: Biolex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more

Conditions: Heart Failure
Interventions: Anakinra; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C Virus
Interventions: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more

Conditions: HCV Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 34 more

Conditions: Chronic Hepatitis C
Interventions: Viramidine, Ribavirin, pegylated interferon alfa-2a; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more

Conditions: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: PPI-461, Placebo; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hepatitis C
Interventions: BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more

Conditions: Chronic Hepatitis C
Interventions: Not listed
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 20 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Hepatitis C, Cirrhosis
Interventions: daclatasvir, Sofosbuvir, Sovaldi, Ribavirin; Drug
Lead sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Coronado, California

Conditions: HCV Infection
Interventions: ABT-333, ketoconazole, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Hepatitis C
Interventions: Patient-Centered Electronic App; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: DCV 3DAA FDC, BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions: Dietary and Lifestyle modification educational sessions; Behavioral
Lead sponsor: Hossam Kandil; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C, HIV, Risk Reduction Behavior
Interventions: Peer Mentor; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions: OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 50 Years to 64 Years
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more

Conditions: Hepatitis B Infection, Hepatitis C Infection, HIV Infection
Interventions: hepatitis B vaccine 3 dose schedule (0,1,2 month), HBV Vaccination Self-Efficacy Intervention; Biological · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
Interventions: MI-based HIV Risk Reduction; Other
Lead sponsor: Michele Staton; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Hazard, Kentucky

Conditions: Hepatitis C
Interventions: Hepatitis C Treatment Alerts in CHORUS™, Standard of Care; Other
Lead sponsor: Epividian; Industry
Eligibility: 18 Years and older
Enrollment: 1,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Atherosclerosis
Interventions: Patient counseling for HCV associated CVD risk factors; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

Brief Intervention for Rural Women at High Risk for HIV/HCV

Hepatitis C Diagnosis to Treatment Management

Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors